Application of compound HG9-91-01, darafenib, AZD5423, GSK840 or HS-1371 in preparation of medicine for preventing and treating retina hypoxic ischemic injury

Compound HG9-91-01 and other drugs used to prepare retinal hypoxic ischemic injury. By protecting retinal and optic nerve cells, the treatment problems of acute glaucoma and retinal hypoxic ischemic injury have been solved, and the optic ganglion has been significantly improved. Cell survival rate and protect retinal structure.

CN119074735APending Publication Date: 2024-12-06GUANGZHOU NAT LAB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411223493.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art lacks effective neuroprotective drugs in the treatment of acute glaucoma and retinal hypoxic ischemic injury, resulting in damage and death of retinal nerve cells, which in turn affects vision.

Method used

Compounds HG9-91-01, dalafenib, AZD5423, GSK840 or HS-1371 and their derivatives are used to prepare drugs to prevent and treat retinal hypoxic ischemic injury, which reduces apoptosis by protecting the retina and optic nerve cells. , necrotic apoptosis and pyroptosis, reducing the thickness of the retinal cell layer.

Benefits of technology

Compounds HG9-91-01, etc., significantly improve the survival rate of optic ganglion cells, protect the retinal structure, provide supplementary therapy for glaucoma caused by acute intraocular pressure, and provide new for retinal hypoxia and ischemic injury. Therapeutic potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074735A_ABST
    Figure CN119074735A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicinal chemistry, and relates to an application of compounds HG9-91-01, darafenib, AZD5423, GSK840, HS-1371 or derivatives thereof in preparation of drugs for preventing and treating hypoxic ischemic retinal injury. The invention researches the influence of the compound on an in-vivo model (acute intraocular hypertension) / in-vitro model (sugar oxygen deprivation) of retinal hypoxia ischemic injury, and the result shows that the compound can play a neuroprotective role on optic ganglion cells (RGCs) under the invasion of sugar oxygen deprivation (OGD), and the HG9-91-01 can protect the retina structure in the acute intraocular hypertension model, and can be used for preparing a neuroprotective drug for treating retinal hypoxia ischemic injury. The problem that the number of neuroprotective drugs for RGCs in the retinal hypoxic ischemic injury is small is solved, a supplementary therapy is provided for intraocular pressure reduction treatment of glaucoma caused by acute intraocular pressure rise, and a new potential candidate drug is further provided for protecting the retinal hypoxic ischemic injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medicinal chemistry, and in particular to use of compounds HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 or derivatives thereof in preparing drugs for preventing and treating retinal hypoxic-ischemic damage. Background Art

[0002] Ischemic retinopathy refers to a series of diseases caused by retinal tissue hypoxia and ischemia, which leads to damage of retinal blood vessels, and then causes retinal tissue edema, exudation, hemorrhage and pathological changes of optic ganglion cells, mainly including glaucoma, retinal vein occlusion, diabetic retinopathy or central retinal artery occlusion, etc. These diseases are the main causes of blindness in adults and infants worldwide.

[0003] In recent years, research on the protection of retinal hypoxic-ischemic damage has gradually become a hot topic in the field of ophthalmology, including the active development of neuroprotective drugs, drugs to improve blood circulation, laser and vitrectomy, etc. However, since its overall pathogenesis has not been fully elucidated, there has been no breakthrough in treatment, especially the inability to curb the progressive deterioration of retinal nerve cells after hypoxic-ischemic damage.

[0004] Retinal ganglion cells (RGCs) are a very important type of nerve cells in the visual pathway. RGCs respond to light stimulation and encode light signals into electrical signals, which are transmitted to the visual cortex and other visual processing centers of the brain through axons. Therefore, they play an irreplaceable role in the transmission of visual information. Damage or death of RGCs can lead to impaired visual function and even permanent blindness. Studying the molecular mechanism of RGCs helps to understand the pathological process of retinal damage and is of great significance for the treatment of retinal diseases and the protection of vision. Therefore, when studying retinal damage, RGCs are the main research object.

[0005] Glaucoma is one of the major hypoxic-ischemic retinal damage diseases and the second leading cause of blindness worldwide. It is estimated that the global prevalence of glaucoma in people aged 40 to 80 years is 3.5%. If not treated in time, it can lead to a rapid increase in intraocular pressure, secondary optic nerve damage, and then blindness. Lowering intraocular pressure has been shown to be effective in preventing the occurrence of glaucomatous diseases and delaying disease progression. However, even after receiving intraocular pressure-lowering treatment, 12% of patients still experienced glaucomatous optic disc progression or visual field loss during a 5-year follow-up period. This evidence shows that simply lowering intraocular pressure cannot prevent the disease from worsening in all patients. Reconstructing the damaged optic nerve pathways of RGCs has great potential in the treatment of acute glaucoma.

[0006] Compounds HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 are all highly effective inhibitors targeting RIPK3. Previous studies have mainly focused on the antidepressant, immunomodulatory and glucose metabolism effects of RIPK3 inhibitors. However, there have been no studies or reports on the use of HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 for the prevention and treatment of acute glaucoma. Since the main pathological feature of glaucoma caused by acute high intraocular pressure is hypoxic-ischemic damage to the retina, we used the acute high intraocular pressure model as an in vivo model to study typical hypoxic-ischemic damage to the retina. Summary of the invention

[0007] Therefore, the technical problem to be solved by the present invention is to provide a use of a compound HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 or a derivative thereof in the preparation of a drug for preventing and treating hypoxic-ischemic retinal damage.

[0008] To this end, the present invention provides the following technical solutions:

[0009] Use of compound HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 or derivatives thereof in the preparation of drugs for preventing and treating retinal hypoxic-ischemic damage.

[0010] Optionally, the retinal hypoxic-ischemic damage refers to retinal cell hypoxic-ischemic damage caused by various reasons, including but not limited to glaucoma, retinal vein occlusion, diabetic retinopathy or central retinal artery occlusion.

[0011] Use of the compound HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 or a derivative thereof in the preparation of a drug for protecting the retina and / or optic nerve.

[0012] Optionally, the protection of the retina and / or optic nerve is to increase the survival rate of retinal ganglion cells under glucose-oxygen deprivation, reduce apoptosis, pyroptosis and necroptosis of retinal cells induced by hypoxic-ischemic damage, and / or reduce the damage to the retinal cell layer thickness induced by hypoxic-ischemic damage.

[0013] Optionally, the impaired thickness of the retinal cell layers includes impaired thickness of the GCL, IPL, INL, OPL and / or ONL of the retina.

[0014] Optionally, compound HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 or its derivatives include cis-trans isomers, diastereomers, geometric isomers, racemates, solvates, pharmaceutically acceptable salts, prodrugs or derivatives substituted with at least one atom or atomic group.

[0015] A pharmaceutical preparation for preventing and treating retinal hypoxic-ischemic damage comprises the compound HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 or derivatives thereof, and pharmaceutically acceptable excipients.

[0016] Optionally, the pharmaceutical preparation is in the form of a liquid preparation, a semisolid preparation or a solid preparation.

[0017] Optionally, the pharmaceutical preparation is an oral preparation or an external preparation.

[0018] Optionally, the dosage form of the pharmaceutical preparation includes powder, powder injection, injection, tablet, capsule, granule, paste, paint, lotion, tincture, liniment, coating, ointment, gel, paste, patch or aerosol.

[0019] Optionally, the auxiliary materials include any one or a combination of at least two of carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers.

[0020] The technical solution of the present invention has the following advantages:

[0021] 1. The present invention provides compounds HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 or their derivatives for the preparation of drugs for preventing and treating retinal hypoxic-ischemic damage; the present invention studies the effects of the above-mentioned small molecule compounds HG9-91-01 and the like on an in vivo model (acute intraocular hypertension) / in vitro model (glucose-oxygen deprivation) of retinal hypoxic-ischemic damage, and the results show that HG9-91-01 and the like can exert a neuroprotective effect on retinal ganglion cells (RGCs) under the invasion of glucose-oxygen deprivation (OGD), and HG9-91-01 can protect the retinal structure in the acute intraocular hypertension model, which solves the problem of the lack of neuroprotective drugs for RGCs in retinal hypoxic-ischemic damage, provides a supplementary therapy for the intraocular hypertension treatment of glaucoma caused by acute intraocular hypertension, and further provides a new potential candidate drug for protecting retinal hypoxic-ischemic damage. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0023] Figure 1 This is the experimental procedure of the cell OGD model in Example 1 of the present invention for simulating hypoxic-ischemic injury of RGCs in vitro;

[0024] Figure 2 The effects of five compounds of different concentrations identified by CCK8 in Example 1 of the present invention on the cell survival rate of RGCs after OGD injury;

[0025] Figure 3 In Example 1 of the present invention, a common optical microscope was used to observe the cell morphological changes of RGCs in different groups at a concentration of 40 μM;

[0026] Figure 4 It is the result that HG9-91-01 treatment in Example 1 of the present invention can reduce PANoptosis (apoptosis, necroptosis and pyroptosis) of RGCs induced by OGD; Figure A is the TUNEL staining image of RGCs in each group and the quantitative analysis of TUNEL positive cells; Figure B is the immunofluorescence staining of RGCs in each group for GSDMD and the quantitative analysis of GSDMD positive cells; Figure C is the PI staining image of RGCs in each group and the quantitative analysis of PI positive cells;

[0027] Figure 5 This is the experimental protocol flow of the acute intraocular hypertension (AOH) mouse model in Example 1 of the present invention for simulating retinal hypoxic-ischemic damage caused by pathological intraocular pressure elevation in vivo;

[0028] Figure 6 The effect of HG9-91-01 in Example 2 of the present invention on the retinal structure and the expression level of TUNEL-positive cells in AOH mice; Figure A and Figure C are representative HE staining images of each group and quantitative analysis of retinal thickness; Figure B and Figure D are representative images of the retina labeled with TUNEL (green) and DAPI (blue) of each group and quantitative analysis of TUNEL-positive cells;

[0029] Figure 7: is the effect of HG9-91-01 in Example 2 of the present invention on the expression level of apoptosis-related proteins in AOH mice; Figure A is a quantitative evaluation of the protein levels of Bax, Bcl2, total-caspase 3, cleaved-caspase 3, total-caspase 7, cleaved-caspase 7, total-caspase 8 and cleaved-caspase8 by Western blot and gray value analysis; Figures B, C, D, and E are representative images of immunofluorescence staining of Bax, Bcl2, cleaved-caspase 3 and cleaved-caspase 8 in each group;

[0030] Figure 8 : is the effect of HG9-91-01 in Example 2 of the present invention on the expression level of pyroptosis-related proteins in AOH mice; Figure A is the protein levels of total-caspase 1, cleaved-caspase 1, GSDMD, NLRP3 and ASC evaluated by Western blot; Figure B is the gray value analysis and quantification of these proteins; Figure C is a representative image and quantitative analysis of GSDMD immunofluorescence staining;

[0031] Fig. 9 It is the effect of HG9-91-01 in Example 2 of the present invention on the expression level of necroptosis-related proteins in AOH mice; Figure A is the protein levels of p-MLKL, t-MLKL, p-RIPK1, t-RIPK1, p-RIPK3 and t-RIPK3 evaluated by Western blot; Figure B is the gray value analysis and quantitative analysis of these proteins. DETAILED DESCRIPTION

[0032] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.

[0033] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.

[0034] The small molecule compound HG9-91-01 in the following examples has a CAS number of 1456858-58-4 and a structural formula as follows:

[0035]

[0036] Dabrafenib, CAS No.: 1195765-45-7, has the following structural formula:

[0037]

[0038] AZD5423, CAS No.: 1034148-04-3, its structural formula is as follows:

[0039]

[0040] GSK840, CAS No.: 2361146-30-5, its structural formula is as follows:

[0041]

[0042] HS-1371, CAS No.: 2158197-70-5, its structural formula is as follows:

[0043]

[0044] The above compounds HG9-91-01, dabrafenib, AZD5423, GSK840 and HS-1371 are all commercially available products.

[0045] Example 1 In vitro experiment

[0046] 1. Purpose of the experiment

[0047] The retinal ganglion cell glucose-oxygen deprivation model was used to simulate hypoxia-ischemia in vitro, and the neuroprotective effects of small molecule compounds HG9-91-01, Dabrafenib, AZD5423, GSK840 and HS-1371 on glucose-oxygen deprivation of rat retinal ganglion cells (RGCs) were detected. In this example, HG9-91-01, Dabrafenib, AZD5423, GSK840 and HS-1371 were used as treatment groups to compare their neuroprotective effects on RGCs with those of the control group, as well as the difference in efficacy compared with HG9-91-01.

[0048] 2. Experimental Methods

[0049] 2.1. Primary cell culture of RGCs and construction and grouping of OGD models

[0050] RGCs (purchased from Procell, Wuhan, China) were cultured in a humidified incubator at 37°C and 5% CO2. The cell culture medium was changed every 2-3 days. The OGD model was used to simulate hypoxic-ischemic cell injury in vitro. The experimental protocol was as follows Figure 1 , the specific process is as follows:

[0051] Control group, conventionally cultured RGCs.

[0052] In the OGD group, conventionally cultured RGCs (6-well plate, 2.5×10 per well) were placed in the 6 The initial culture medium (culture medium: iCell primary neuronal cell cultivation system, purchased from procell) in the RGCs was replaced with sugar-free EBSS medium (purchased from Solebow Technology Co., Ltd.), and the RGCs were cultured in a hypoxic chamber (a mixture of 94% N2, 1% O2 and 5% CO2) for 4 hours, and then the sugar-free culture medium was replaced back to the initial culture medium, and then returned to the conventional culture environment (37°C, 5% CO2 humidified incubator) for culture for 4 hours.

[0053] HG9-91-01 group (or OGD+HG9-91-01), HG9-91-01 was dissolved in dimethyl sulfoxide (DMSO) to prepare a mother solution, and then the mother solution was diluted to 10 μM, 20 μM and 40 μM with culture medium (iCell primary cell culture system), and the medium containing the drug was added to the RGCs cell culture plate. The final concentration of the drug in the RGCs cell culture plate was 10 μM, 20 μM or 40 μM, and pre-incubated for 1 hour before the start of OGD. After the pre-incubation, the culture medium in the cultured RGCs was replaced with a sugar-free EBSS medium containing the drug (purchased from Solebold Technology Co., Ltd.), and the RGCs were placed in an anoxic chamber (a mixture of 94% N2, 1% O2 and 5% CO2) for 4 hours, and then the sugar-free medium was replaced with the initial medium without the drug (iCell primary cell culture system), and then returned to the conventional culture environment (37°C, 5% CO2 humidified incubator) for 4 hours;

[0054] The difference between the Dabrafenib group and the HG9-91-01 group is that the drug is replaced by Dabrafenib.

[0055] The AZD5423 group differs from the HG9-91-01 group in that the drug was replaced with AZD5423.

[0056] The GSK840 group differs from the HG9-91-01 group in that the drug is replaced with GSK840.

[0057] The HS-1371 group differs from the HG9-91-01 group in that the drug was replaced with HS-1371.

[0058] Finally, the treated cells of each group were collected for the following experiments.

[0059] 2.2 The CCK8 kit was used to determine the cell survival rate of each group and observe the changes in cell morphology before and after OGD;

[0060] Cell viability: Cells were cultured in 96-well plates and mixed with cell culture medium and CCK8 working solution (purchased from Beijing Solebow Technology Co., Ltd.) at a volume ratio of 10:1 to obtain a mixed culture medium. Then, the initial culture medium was replaced with the mixed culture medium (100 μL per well) and cultured in a conventional incubator in the dark for 1 hour. Finally, the optical density (OD 450nm ) values ​​and calculated the cell survival rate, survival rate (%) = (OD 450nm Value-blank control group OD 450nm value) / (control group OD 450nm Value-blank control group OD 450nm value)×100%.

[0061] Morphological observation: The cells were cultured in 6-well plates. After OGD, the morphological changes of cells in each group were observed under an optical microscope. The drug concentration in the drug-treated group was 40 μM.

[0062] 2.3 Cells were cultured in 6-well plates, and cells were collected and subjected to TUNEL staining, PI staining, and immunofluorescence (GSDMD protein) staining

[0063] TUNEL staining: First, fix the cells with 4% paraformaldehyde. Subsequently, the antigens were repaired and blocked. Then the TUNEL reaction solution (purchased from Wanlei Biotechnology Co., Ltd.) was dropped on the cell sample and incubated in the dark at room temperature for 1 hour. After thoroughly washing the reaction solution with TBS / T (purchased from Solebold Technology Co., Ltd.), the cell nuclei were stained with DAPI dye (purchased from Solebold Technology Co., Ltd.). Anti-fluorescence quencher (purchased from Biyuntian Biotechnology Co., Ltd.) was applied, and then the sample was sealed with neutral gum. The expression of TUNEL-positive cells was observed using a Leica inverted microscope, and images were taken;

[0064] PI staining: Annexin V-FITC / PI kit (purchased from Bio-Tech Biotech Co., Ltd.) was used to identify PI-positive cells. PI working solution was added directly to the 6-well plate according to the manufacturer's instructions. After incubation in the dark for 15 minutes, the samples were washed and sealed as above. Images were taken using a Leica inverted microscope;

[0065] Immunofluorescence staining (GSDMD protein): Cell samples were fixed with 4% paraformaldehyde, followed by antigen repair and blocking. Incubated with primary antibody (GSDMD protein) overnight at 4°C. The next day, samples were incubated with corresponding secondary antibodies and nuclear staining was performed with DAPI dye. Samples were observed and images were collected using a Leica inverted microscope.

[0066] 2.4 Data processing: All data are expressed as mean ± SD. GraphPad Prism8 software was used for drawing and statistical analysis. When three or more groups were compared, one-way analysis of variance was used, followed by Turkey's test for multiple comparisons. P < 0.05 was considered statistically significant, # indicates P < 0.05 compared with the Control group, ## indicates P < 0.01 compared with the Control group, * indicates P < 0.05 compared with the OGD group, and ** indicates P < 0.01 compared with the OGD group.

[0067] 3. Experimental results

[0068] The results showed that, overall, the survival rate of RGCs increased with the increase in drug concentration. When the drug concentration was 10 μM, only the cell survival rate of the HG9-91-01 group was significantly different from that of the OGD group, indicating that the other four drugs may not have reached an effective concentration. When the concentration was increased to 40 μM, all five treatment groups showed considerable statistical differences compared with the OGD group, with the HG9-91-01 group having the highest cell survival rate (see Appendix Figure 2 );

[0069] 2. Under an optical microscope, among the five compound experimental groups, the 40 μM concentration of HG9-91-01 group showed the best cell morphology and the highest cell density (see Appendix Figure 3 ); The above in vitro experimental results support that compounds HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 can protect RGCs from hypoxic-ischemic damage, and HG9-91-01 has the best protective effect among these five compounds; Based on the above cell experimental results, we further infer that HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 also have the effect of protecting retinal structure and retinal neurons in animal experiments, and further infer that these compounds have the potential to alleviate vision loss by exerting a neuroprotective effect on the retina;

[0070] 3. The effect of HG9-91-01 on PANoptosis was explored from the perspectives of apoptosis, necroptosis and pyroptosis. The results showed that compared with the OGD group, the number of TUNEL+ cells was significantly reduced after OGD+HG9-91-01 treatment, which preliminarily indicated that HG9-91-01 could inhibit the apoptosis of RGCs. The activation of GSDMD leads to the initiation of inflammatory response and the occurrence of pyroptosis. The study showed that the changing trend of GSDMD+ cells after OGD was consistent with that of TUNEL+ cells, and the number of GSDMD+ cells increased significantly, while HG9-91-01 treatment could reverse this change, indicating that HG9-91-01 could inhibit cell pyroptosis. In some literature, PI staining is considered to be a specific staining for necroptosis. It was observed that OGD damage led to a significant increase in the number of PI+ cells, and treatment with HG9-91-01 could alleviate this phenomenon, indicating that HG9-91-01 could inhibit necroptosis (see Appendix). Figure 4 (A, B, and C in the figure).

[0071] In summary, the above cell experimental measurements showed that HG9-91-01 exhibited the most effective therapeutic effect among the five compounds, and HG9-91-01 could exert a neuroprotective effect on RGCs after OGD injury by inhibiting PANoptosis (apoptosis, necroptosis, and pyroptosis).

[0072] Example 2 In vivo experiment

[0073] 1. Experimental purpose: The AOH mouse model is used to simulate the retinal hypoxic-ischemic damage caused by pathological intraocular pressure elevation in vivo. This example detects the retinal protective effect of the small molecule compound HG9-91-01 on the acute high intraocular pressure model to explore the pathophysiological mechanism by which this neuroprotection works. In this example, the changes in the thickness of each layer of the retina in the HG9-91-01 treatment group and the control group were compared to discuss whether HG9-91-01 can protect the retina from acute intraocular pressure elevation, and the relationship between this protective effect and the death mode of PANoptosis.

[0074] 2. Experimental Methods

[0075] 2.1 Construction of AOH animal model and grouping

[0076] The AOH model is used to simulate the pathological increase in intraocular pressure in vivo. Mice (8-10 weeks old C57BL / 6 male mice (20-30 g)) were randomly divided into three groups (n = 40 in each group). The protocol flow is as follows Figure 5 , grouped as follows:

[0077] Normal group: PBS containing the same concentration of dimethyl sulfoxide (the solvent of the dosing solution of the HG9-91-01 group is the same as that of the HG9-91-01 group, except that it does not contain HG9-91-01 drug) was intraperitoneally injected into normal mice at 11:00 am every day with a sterile syringe. The drug was administered every day from the 1st day to the 7th day after modeling;

[0078] In the AOH group, mice were deeply anesthetized with 1% sodium pentobarbital (70 mg / kg) and surface anesthetized with proparacaine hydrochloride eye drops. After disinfection, tropicamide-epinephrine eye drops (purchased from Shenyang Xingqi Eye Drug Co., Ltd.) were used to dilate the pupil. A 30G novo needle was connected to a precision filtered infusion set filled with sterile saline and then pierced into the anterior chamber of the right eye. 0.9% saline was raised to a height of 1.5 meters to produce a pressure of 110 mmHg, and the acute AOH model was obtained after continuous ocular pressure for 90 minutes;

[0079] For the HG9-91-01 group (or AOH+HG9-91-01), the HG9-91-01 stock solution (concentration of 8 mM) was diluted with sterile PBS to a final concentration of 40 μM / L. The drug was intraperitoneally injected into acute AOH model mice with a sterile syringe at 11:00 am every day. The dose was 20 mg (HG9-91-01) / kg (mouse body weight) / day, and the drug was administered every day from the 1st day to the 7th day after modeling. The HG9-91-01 stock solution was prepared by dissolving HG9-91-01 in dimethyl sulfoxide (DMSO).

[0080] During the administration period, mice in each group were fed normally. After the administration, samples were collected as follows:

[0081] 1) Paraffin section collection:

[0082] (1) Mouse killing and eye removal

[0083] Kill mice: Kill mice by cervical dislocation to ensure a quick and painless death.

[0084] Expose the eyeball: Use scissors to cut the eyelids and eye canthus of the mouse to expose the eyeball. Avoid damaging the eyeball and surrounding tissues.

[0085] Remove the eyeball: Use ophthalmic forceps to gently clamp the optic nerve at the back of the eyeball and gently pull the eyeball upward. During this process, make sure not to squeeze or pull the eyeball to prevent retinal detachment.

[0086] (2) Eye fixation

[0087] Immediately place the removed eyeball into a container filled with eyeball fixative. The volume of the fixative is usually more than 20 times the volume of the eyeball to ensure that the eyeball can be fully fixed.

[0088] Fix overnight in a 4°C refrigerator.

[0089] (3) Washing and dehydration

[0090] After fixation, the eyeballs were washed with PBS buffer to remove the residual fixative.

[0091] Dehydrate with anhydrous ethanol gradient. Dehydrate in the order of concentration from low to high (30%, 50%, 70%, 80%, 95%, 100%), soak for 1 hour in each concentration gradient to ensure that the water in the eyeball is completely removed.

[0092] (4) Transparent and wax-impregnated

[0093] After dehydration, the eyeball was placed in a mixture of anhydrous ethanol and xylene for transparency treatment to remove residual water in the eyeball and make it transparent.

[0094] The eyeballs were then moved into a pure paraffin solution and immersed for 4 hours to allow the paraffin to fully penetrate into the eyeball tissue.

[0095] (5) Embedding and sectioning

[0096] Place the wax-soaked eyeball tissue into an embedding box and add melted paraffin for embedding.

[0097] After the paraffin has cooled and solidified, use a microtome to cut the paraffin block into 5-micron slices.

[0098] 2) Mouse retinal cell protein collection

[0099] (1) Killing of mice and removal of eyeballs

[0100] Kill mice: Kill mice by cervical dislocation to ensure a quick and painless death.

[0101] Expose the eyeball: Use scissors to cut the eyelids and eye corners of the mouse to expose the eyeball. Be careful not to damage the eyeball and surrounding tissues.

[0102] Remove the eyeball: Use ophthalmic forceps to gently clamp the optic nerve at the back of the eyeball and gently pull the eyeball upward. During this process, make sure not to squeeze or pull the eyeball to prevent retinal detachment.

[0103] (2) Retinal detachment

[0104] Removal of extraocular tissue: Under a microscope, use ophthalmic scissors and ophthalmic forceps to remove the cornea, sclera and other extraocular tissues on the surface of the eyeball to expose the retina.

[0105] Separate the retina: Use ophthalmic forceps to gently grasp the edge of the retina and carefully separate the retina from the wall of the eyeball. Pay attention to maintaining the integrity of the retina and avoiding contamination.

[0106] (3) Retinal tissue lysis and protein extraction

[0107] Tissue Lysis:

[0108] Place the separated retinal tissue into a pre-cooled EP tube and add an appropriate amount of RIPA lysis buffer (lysis buffer preparation: prepare lysis buffer on ice at a ratio of RIPA: cocktail: PMSF of 100:2:1 for later use. 40 μL lysis buffer is required for every two retinas).

[0109] The tissue was lysed using an ultrasonic cell disruptor to ensure that the tissue was fully lysed.

[0110] Centrifugation and supernatant removal:

[0111] The lysed tissue samples were placed in a pre-cooled centrifuge for centrifugation (4°C, 12000 rpm for 30 minutes) to remove cell debris and unlysed tissue.

[0112] Carefully transfer the supernatant (i.e., lysate containing protein) to a new pre-cooled EP tube to avoid aspirating the precipitate.

[0113] (4) Protein preservation

[0114] Protein preservation: The extracted protein samples were stored in a -80°C refrigerator to prevent protein degradation.

[0115] 2.2 HE staining to preliminarily identify the short-term protective effect of HG9-91-01 treatment on the retina

[0116] Paraffin sections were used for HE staining. The retinal structure was observed and photographed using a common optical microscope. Image J software was used to measure the thickness of the ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), and outer nuclear layer (ONL) in each group;

[0117] 2.3 Retinal tissues of animals in each group were collected for TUNEL staining, immunofluorescence staining and Western blot

[0118] TUNEL staining: After the retinal tissue is made into paraffin sections, the paraffin sections are gradiently dewaxed. The subsequent steps are the same as the TUNEL staining method in Example 1;

[0119] Immunofluorescence staining: After the retinal tissue is made into paraffin sections, the paraffin sections are gradiently dewaxed. The subsequent steps are the same as the immunofluorescence staining method in Example 1; wherein the primary antibody used for incubation is a key protein related to PANoptosis (see the table below);

[0120] Table 1. Primary Antibodies

[0121]

[0122]

[0123] Western blot: After extracting proteins from the retina, quantitative analysis was performed using a BCA kit (purchased from Thermo Fisher Scientific Inc.) and normalized to the same concentration. Protein samples were separated by SDS-PAGE gel and transferred to a PVDF membrane. After blocking with BSA, the membrane was incubated with the primary antibody overnight at 4°C. The primary antibody used for incubation was a key protein associated with PANoptosis (see Table 1 above); the next day, the membrane was incubated with the corresponding secondary antibody (specifically goat anti-mouse secondary antibody and goat anti-rabbit secondary antibody) at room temperature for 1 hour. The membrane was developed under chemiluminescent solution, and the grayscale value of each group was measured using Image J software.

[0124] 2.4 Data processing: All data are expressed as mean ± SD. GraphPad Prism8 software was used for drawing and statistical analysis. When three or more groups were compared, one-way analysis of variance was used, followed by Turkey's test for multiple comparisons. P < 0.05 was considered statistically significant, # indicated P < 0.05 compared with the normal group, ## indicated P < 0.01 compared with the normal group, * indicated P < 0.05 compared with the AOH group, and ** indicated P < 0.01 compared with the AOH group.

[0125] 3. Experimental results:

[0126] 3.1. In order to evaluate the beneficial effects of HG9-91-01 on the retina, eyeball tissues were removed 7 days after AOH injury for HE staining and the thickness of each retinal cell layer was measured (see Appendix Figure 6 Figures A and C in the middle). Seven days after AOH injury, the thickness of the GCL, IPL, INL, OPL, and ONL showed varying degrees of damage, and HG9-91-01 treatment significantly alleviated these injuries. Compared with the normal group, the thickness of the five cell layers (GCL, IPL, INL, OPL, and ONL) in the AOH group decreased to 56%, 66%, 63%, 68%, and 66% of that in the normal group, respectively. Compared with the AOH group, HG9-91-01 treatment resulted in the thickness of each layer being 1.36 times, 1.27 times, 1.60 times, 1.38 times, and 1.34 times that of the AOH group. However, the retinal thickness of the HG9-91-01-treated group did not fully recover to its normal level before injury. These results indicate that HG9-91-01 has a significant protective effect on the retinal structure after AOH injury in the short term, but this protective effect is limited, and HG9-91-01 treatment cannot completely restore the retinal structure to its original state;

[0127] 2. Cells marked as TUNEL positive indicate that apoptosis has occurred. Figure 6 As shown in Figures B and D, the number of TUNEL-positive cells in the retina of mice in the AOH group increased significantly compared with the normal group, and HG9-91-01 treatment effectively reversed this change. In addition, it was observed that TUNEL-positive cells were mainly concentrated in the GCL and INL layers, while the ONL layer was scattered. It is speculated that different types of cells have different sensitivities to pathological high intraocular pressure. In fact, after AOH damage, cells in all layers of the retina will initiate apoptosis programs to varying degrees;

[0128] 3. To further confirm the association between HG9-91-01 treatment and retinal cell apoptosis, Western blot and immunofluorescence staining were performed, and the expression levels of major proteins associated with cell apoptosis after AOH injury were evaluated (see Appendix Figure 7 Figures A, B, C, D, and E in the middle). Western blot results showed that total-caspase 3 (TC3), total-caspase 7 (TC7), and total-caspase 8 (TC8) in the three groups of mice did not change significantly, but their activated forms cleaved-caspase3 (C-C3), cleaved-caspase 7 (C-C7), and cleaved-caspase 8 (C-C8) increased significantly after AOH injury; this change was significantly reduced after the mice were injected with HG9-91-01. In addition, compared with the normal group, the expression level of the pro-apoptotic protein BAX in the AOH group was significantly increased, while the expression level of the anti-apoptotic protein BCL2 was significantly decreased, and the ratio of BCL2 / BAX was also reduced, and these effects were partially reversed after treatment with HG9-91-01. The immunofluorescence results were consistent with the Western blot results. BCL2, BAX, cleaved-caspase 3, and cleaved-caspase 8 were clearly observed in the GCL layer, indicating that RGCs initiated apoptosis after AOH injury. The study preliminarily proved that HG9-91-01 can inhibit retinal cell apoptosis in mice after AOH injury, thereby playing a protective role;

[0129] 4.Western blot was used to study the effect of HG9-91-01 on pyroptosis in retinal cell populations and the expression levels of NLRP3, caspase 1, GSDMD and ASC were analyzed. Figure 8Figures A, B, and C show that although the total level of caspase1 (TC1) remained relatively stable before and after AOH injury, the levels of cleaved caspase1 (the activated form of caspase1, CC1), NLRP3, GSDMD, and ASC increased significantly after AOH injury. Importantly, the expression of these proteins decreased after injection of HG9-91-01. The immunofluorescence results were consistent with the western blot results, further indicating that the level of GSDMD in the drug-treated group was significantly decreased, and the expression of GSDMD was mainly localized in the GCL and INL layers. In summary, HG9-91-01 exerts a protective effect by inhibiting AOH-induced pyroptosis in retinal cell populations;

[0130] 5. The study found that compared with the normal group, the expression levels of total-MLKL, total-RIPK1 and total-RIPK3 in the AOH group were significantly increased, and the ratios of p-MLKL (phosphorylated MLKL) / GAPDH, p-RIPK1 (phosphorylated RIPK1) / GAPDH and p-RIPK3 (phosphorylated RIPK3) / GAPDH in the AOH group were also higher than those in the normal group, while HG9-91-01 treatment reversed this change (see Appendix Fig. 9 These findings suggest that necroptosis is widespread in retinal cell populations after AOH injury and that HG9-91-01 can protect the retina by inhibiting necroptosis.

[0131] In summary, the above experimental measurements show that HG9-91-01 can protect the retina from hypoxic-ischemic damage caused by acute pathological increase in intraocular pressure. This protective effect is produced by inhibiting the expression levels of key proteins highly related to PANoptosis, thereby inhibiting the PANoptosis death mode.

[0132] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. Use of compound HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 or their derivatives in the preparation of a drug for preventing and treating retinal hypoxic-ischemic damage.

2. The use according to claim 1, characterized in that The retinal hypoxic-ischemic injury includes, but is not limited to, glaucoma, retinal vein occlusion, diabetic retinopathy or central retinal artery occlusion.

3. Use of the compound HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 or its derivatives in the preparation of drugs for protecting the retina and / or optic nerve.

4. The use according to claim 3, characterized in that The protection of the retina and / or optic nerve is to increase the survival rate of retinal ganglion cells under glucose-oxygen deprivation, reduce apoptosis, pyroptosis and necroptosis of retinal cells induced by hypoxic-ischemic damage, and / or reduce the thickness of retinal cell layers induced by hypoxic-ischemic damage; Optionally, the impaired thickness of the retinal cell layers includes impaired thickness of the GCL, IPL, INL, OPL and / or ONL of the retina.

5. The use according to any one of claims 1 to 4, characterized in that: Derivatives of compound HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 include cis-trans isomers, diastereomers, geometric isomers, racemates, solvates, pharmaceutically acceptable salts, prodrugs or derivatives substituted with at least one atom or atomic group thereof.

6. A pharmaceutical preparation for preventing and treating hypoxic-ischemic retinal damage, characterized in that: The invention comprises the compound HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 or a derivative thereof as described in any one of claims 1 to 5, and a pharmaceutically acceptable excipient.

7. The pharmaceutical preparation for preventing and treating hypoxic-ischemic retinal damage according to claim 6, characterized in that: The pharmaceutical preparation may be in the form of a liquid preparation, a semisolid preparation or a solid preparation.

8. The pharmaceutical preparation for preventing and treating hypoxic-ischemic retinal damage according to claim 6 or 7, characterized in that: The pharmaceutical preparation is an oral preparation or an external preparation.

9. The pharmaceutical preparation for preventing and treating hypoxic-ischemic retinal damage according to any one of claims 6 to 8, characterized in that: The dosage forms of the pharmaceutical preparation include powder, powder injection, injection, tablet, capsule, granule, paste, paint, lotion, tincture, liniment, coating, ointment, gel, paste, patch or aerosol.

10. The pharmaceutical preparation for preventing and treating hypoxic-ischemic retinal damage according to any one of claims 6 to 9, characterized in that: The auxiliary materials include any one or a combination of at least two of carriers, diluents, excipients, fillers, adhesives, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers.